The future of exercise

Episode Summary

Executive Summary: The episode explores how exercise might be understood and eventually mimicked as medicine by identifying the molecules and pathways it activates. Stanford’s Jonathan Long discusses LAC-FE, a lactate-derived molecule that rises after intense exercise, suppresses appetite, and may link gut, brain, and metabolism. The conversation connects exercise science to obesity, diabetes, metformin, and the long-term prospect of an exercise pill, while stressing that basic science is still in early stages.

Main Topics: Exercise as medicine and the need for molecular definitions (Priority: 5/5): Long argues that to make exercise therapeutically usable, scientists must define its effects in terms of specific molecules, pathways, and targets—similar to how modern drugs are characterized. LAC-FE discovery and appetite suppression (Priority: 5/5): The transcript centers on LAC-FE, a molecule derived from lactate that rises after high-intensity exercise and suppresses feeding, offering a mechanistic explanation for reduced hunger after hard workouts. Gut-brain axis and systemic signaling (Priority: 4/5): Long explains that LAC-FE is produced in intestinal epithelial cells and may act through the gut-brain axis, potentially influencing not just appetite but mood, anxiety, and motivation. Exercise, training status, and species conservation (Priority: 4/5): The discussion compares trained and untrained individuals and notes that LAC-FE responses appear across multiple species, including mice, humans, racehorses, and sled dogs. Diabetes, obesity, and metabolic disease (Priority: 4/5): The episode ties exercise biology to obesity-related diabetes, emphasizing that weight loss itself improves metabolic disease and that LAC-FE may aid weight loss in animal models. Metformin and unexpected pathway convergence (Priority: 4/5): Long reveals that metformin, a diabetes drug increasingly used off-label for longevity, also stimulates the LAC-FE pathway, linking a classic drug to exercise biology. Prospects and limits of an exercise pill (Priority: 5/5): The conversation concludes that an exercise-mimicking pill is plausible but distant, and likely will require multiple compounds or pathway-specific interventions rather than a single drug.

Key Arguments: Exercise benefits should eventually be understood and harnessed at the level of defined molecules and pathways, not just general advice like "150 minutes a week." LAC-FE is a genuine exercise-induced signal, not merely a byproduct, because it suppresses appetite and persists long after lactate returns to baseline. The gut is a key source of LAC-FE, supporting the idea that exercise communicates with the brain through gut-brain signaling. Trained and untrained people differ in lactate handling, which likely changes the magnitude of LAC-FE signaling and may explain different exercise responses. Controlling body weight can improve diabetes and other cardiometabolic diseases, but preserving lean mass while losing fat is the ideal outcome. Metformin and sprint exercise unexpectedly converge on the same LAC-FE pathway, demonstrating that seemingly unrelated interventions can share biology. An exercise pill is conceptually possible, but the field is still in the foundational stage and will require decades of pathway discovery and validation.

Data Points: GLP-1 drug development timeline: ~40 years - Described as the journey from basic science in the 1980s to modern semaglutide-class weight-loss drugs. Recent therapeutic acceleration: ~10 years - The last decade is when pharma recognized and optimized GLP-1 drugs for weight loss. Exercise recommendation: 150 minutes a week - Mentioned as the CDC-style guideline that contrasts with precise drug dosing. LAC-FE persistence in humans after exercise: 12 to 18 hours - After a treadmill test, LAC-FE stays elevated long after lactate returns to baseline. Lactate normalization after exercise: ~1 hour - Lactate comes back to baseline much faster than LAC-FE after intense exercise. Sprint exercise duration example: 10 minutes - Used as an example of a short, intense treadmill effort that raises lactate and LAC-FE.

Pivotal Quotes: "If we really want to make exercise as medicine a reality, what we ought to be able to do is understand the pathways of exercise well enough that we could develop a therapeutic that hijacks exercise pathways so that we can get some of the benefits." — Jonathan Long: Framing the central scientific goal of the research program. "This is where the GLP-1 medicines were in the 1980s. We're just uncovering the fundamental basic sciences and basic understanding of the pathway." — Jonathan Long: Comparing the current stage of exercise-mimetic research to the early era of GLP-1 drug discovery. "These two things you think are very different. Sprinting and this anti-diabetic drug, metformin. Unbelievable. These are actually intimately, intimately connected." — Jonathan Long: Explaining the newly discovered convergence between metformin and exercise on the LAC-FE pathway.

Implications: Exercise science may eventually produce targeted therapies for appetite, metabolism, mood, and muscle preservation, but the field is still early. For now, lifestyle remains essential, and future drugs will likely complement rather than replace exercise.